scholarly article | Q13442814 |
P2093 | author name string | J M Gatell | |
E Soriano | |||
M Bonet | |||
J Traserra | |||
V Araujo | |||
J G SanMiguel | |||
F Ferran | |||
P2860 | cites work | Controlled Comparison of Amikacin and Gentamicin | Q28324094 |
Relationship Between Aminoglycoside-Induced Nephrotoxicity and Auditory Toxicity | Q28327774 | ||
Immediate effects of tobramycin on human cochlea and correlation with serum tobramycin levels | Q28330663 | ||
Ototoxicity of Tobramycin: A Clinical Overview | Q28336416 | ||
Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin | Q28366502 | ||
Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity | Q33727669 | ||
Comparative nephrotoxicities of high-dose netilmicin and tobramycin in rats | Q33732072 | ||
Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin | Q34056699 | ||
Aminoglycoside ototoxicity in the human | Q34057509 | ||
Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule | Q35574233 | ||
Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin | Q35745224 | ||
Pharmacology and efficacy of netilmicin | Q36469912 | ||
Netilmicin in Gram-Negative Bacterial Infections | Q36477089 | ||
Amikacin serum concentrations: prediction of levels and dosage guidelines | Q39214222 | ||
Aminoglycoside antibiotics in infectious diseases. An overview | Q39738119 | ||
Age related changes influencing the effects of drugs and other xenobiotics on sensorineural hearing | Q40203004 | ||
Comparison of Netilmicin and Amikacin in Treatment of Complicated Urinary Tract Infections | Q40619286 | ||
Hyperthermia increases aminoglycoside ototoxicity. | Q40837471 | ||
Comparative Toxicity of Netilmicin and Gentamicin in Squirrel Monkeys (Saimiri sciureus) | Q41407938 | ||
Clinical evaluation of netilmicin therapy in serious infections | Q41435773 | ||
Comparative ototoxic liability of netilmicin and gentamicin | Q42111978 | ||
Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis | Q42248893 | ||
Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans | Q42928339 | ||
Combined effect of noise and neomycin on the cochlea | Q46204029 | ||
Alteration of aminoglycoside antibiotic ototoxicity by hyper- and hypohydration | Q46205404 | ||
Have the new beta-lactams rendered the aminoglycosides obsolete for the treatment of serious nosocomial infections? | Q50579005 | ||
Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. | Q50589543 | ||
Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. | Q50622127 | ||
Alteration of aminoglycoside antibiotic ototoxicity: effect of semistarvation. | Q53925219 | ||
Comparative nephrotoxicity of aminoglycoside antibiotics in rats | Q67404923 | ||
Empirical antimicrobial therapy in the neutropenic host | Q68891378 | ||
A model for predicting nephrotoxicity in patients treated with aminoglycosides | Q69493303 | ||
Tobramycin and amikacin nephrotoxicity. Value of serum creatinine versus urinary concentration of beta-2-microglobulin | Q69919330 | ||
Micro-determination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detection | Q70976303 | ||
Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin | Q72551535 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multivariate statistics | Q1952580 |
P304 | page(s) | 1383-7 | |
P577 | publication date | 1987-09-01 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides | |
P478 | volume | 31 |
Q28316869 | A comparison of netilmicin and tobramycin therapy in patients with renal impairment |
Q40805018 | A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen |
Q48303892 | Adverse effects of a single dose of gentamicin in adults: a systematic review |
Q40766816 | Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia |
Q38919674 | Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review |
Q40720366 | Aminoglycoside dosage regimens. Is once a day enough? |
Q37941557 | Aminoglycoside therapy. Current use and future prospects |
Q38676819 | Aminoglycoside-induced hearing loss in humans |
Q37224123 | Aminoglycoside-induced vestibular injury: maintaining a sense of balance |
Q43872720 | Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? |
Q90589972 | Analysis of drug-induced hearing loss by using a spontaneous reporting system database |
Q38006505 | Antimicrobial therapy for the elderly patient |
Q37060143 | Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis |
Q95728061 | Audiometric threshold shifts after total knee arthroplasty by using gentamicin-loaded bone cement |
Q43787795 | Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections |
Q30240026 | Drug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies |
Q40594113 | Experimental, clinical and preventive aspects of ototoxicity |
Q41817586 | Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit. |
Q42908869 | Management of Aminoglycosides in the Intensive Care Unit |
Q33581183 | Meropenem. A pharmacoeconomic review of its use in serious infections |
Q50530085 | Monitoring of hearing during treatment of leukaemia with special reference to the use of amikacin. |
Q45991071 | No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. |
Q33569075 | Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects |
Q38239743 | Once-daily aminoglycoside administration: new strategies for an old drug |
Q33928699 | Once-daily dosing of aminoglycoside antibiotics |
Q34521641 | Ototoxicity induced by gentamicin and furosemide |
Q40392377 | Parenteral aminoglycoside therapy. Selection, administration and monitoring |
Q28328534 | Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection |
Q33770259 | Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly |
Q40949882 | Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy |
Q33772759 | Prevention of adverse events in hospitalized patients using an antimicrobial review program |
Q92497796 | Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
Q38353565 | Safety and tolerability profile of second-line anti-tuberculosis medications |
Q41138730 | The aminoglycosides |
Q38933875 | The safety and tolerability of the second-line injectable antituberculosis drugs in children. |
Q36095859 | Unique aspects of antimicrobial use in older adults |
Q41435517 | Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations |
Q36446781 | d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models |